2025-04-27 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0. Key Figures Overview:**

RXRX's cumulative return significantly underperforms the S&P 500 (VOO) over the analyzed period.  The stock exhibits high volatility and negative alpha, suggesting underperformance relative to the market.  Recent price action shows a downward trend, supported by negative earnings and fluctuating financial metrics.


**1. Performance Comparison & Alpha/Beta Analysis:**

Recursion Pharmaceuticals Inc. (RXRX) is a clinical-stage biopharmaceutical company leveraging AI and high-throughput screening to discover and develop novel therapies.

* **Cumulative Return (RXRX):** -47.59%
* **Cumulative Return (VOO):** 16.99%
* **Return Difference:** -64.6%  (This means RXRX underperformed VOO by 64.6 percentage points.)
* **Relative Divergence:** 8.4% (This indicates RXRX's underperformance is in the lower 8.4th percentile relative to its historical range of under/outperformance against VOO)

The provided Alpha/Beta analysis reveals consistently negative alpha across the periods (2021-2023, 2022-2024, 2023-2025), indicating underperformance relative to the market.  The high beta (around 4.0) shows significant volatility; RXRX is more sensitive to market movements than the average stock.  Market capitalization has decreased significantly during this period.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.7 | 2.7 |
| 2023-2025  | 4.0% | 73.6% | -12.0% | 2.3 | 2.3 |


**2. Recent Price Movement:**

* **Closing Price:** $5.73
* **Previous Close:** $5.75
* **5-Day Moving Average:** $5.62
* **20-Day Moving Average:** $5.18
* **60-Day Moving Average:** $6.70

The closing price is below all three moving averages, suggesting a short-term downtrend.  The recent price drop (-$0.35) is relatively small and not indicative of a significant market event.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.39 (Medium Risk)
* **RSI:** 69.76 (Approaching overbought territory)
* **PPO:** 2.77 (Positive, suggesting bullish momentum but needs to be considered along with other indicators.)
* **20-Day Relative Divergence Change:** -2.9% (Short-term downward trend)
* **Expected Return:** -397.0% (This extremely negative expected return relative to the S&P 500 is concerning and raises major doubts about long-term investment viability.)

The relatively high RSI suggests potential overbought conditions, while the negative 20-day relative divergence change confirms the recent downward price movement. The extremely negative expected return highlights significant risk.



**4. Recent Earnings Analysis:**

RXRX shows consistent negative EPS and low revenue.  While there was a slight increase in revenue in Q3 2024, overall financial performance remains weak.

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -0.34  | $0.03 B      |
| 2024-08-08 | -0.4   | $0.01 B      |
| 2024-05-09 | -0.39  | $0.01 B      |
| 2023-11-09 | -0.43  | $0.01 B      |
| 2024-11-06 | -0.43  | $0.01 B      |


**5. Financial Information:**

Revenue growth is inconsistent, and profit margins are extremely erratic, swinging between significantly positive and negative values.  Equity has fluctuated, and ROE remains consistently negative, indicating the company is not generating profits relative to its shareholder equity.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |
| 2024-06-30 | $0.01B | 36.14% |
| 2024-03-31 | $0.01B | 17.23% |
| 2023-12-31 | $0.01B | 6.99% |


**Capital and Profitability:**

| Quarter | Equity | ROE     |
|---------|---------|---------|
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |
| 2024-06-30 | $0.58B | -16.69% |
| 2024-03-31 | $0.40B | -22.78% |
| 2023-12-31 | $0.46B | -20.07% |


**6. Overall Analysis:**

RXRX demonstrates significant underperformance compared to the S&P 500, marked by consistently negative alpha and high beta.  Recent price action, technical indicators, and financial statements paint a concerning picture.  Negative earnings, inconsistent revenue, and erratic profitability raise significant concerns about the company's long-term viability.  The extremely negative projected return relative to the S&P 500 strongly advises against long-term investment unless significant changes in the company's fundamentals occur.  Further due diligence and careful risk assessment are crucial before considering any investment in RXRX.  The high volatility should be especially noted.
